MDGL•benzinga•
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
Summary
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 26, 2025 by benzinga